Search Results

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“ Kane ”) announces that, it has completed the sale of its interest in STEM Animal Health Inc. to Dechra Veterinary Products, Inc. for US $8,000,000, plus net cash held in STEM (estimated at CND $600,000) and a working capital adjustment (estimated at CND $350,000) (the “ Transaction ”).

DW Healthcare Partners (“DWHP”) a healthcare-focused private equity firm, announced the closing of its sale of Med-Pharmex Holdings, Inc (“Med-Pharmex”, or the “Company”) to Dechra Pharmaceuticals PLC (“Dechra”). Med-Pharmex is a leading, fully-integrated veterinary pharmaceutical manufacturer focused on developing, manufacturing, and commercializing animal health drugs.

Kane Biotech Inc., and Dechra Veterinary Products LLC announced the expansion of their 10-year Exclusive License and Distribution Agreement to include South America.

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its first quarter 2024 financial results.

Kindred Biosciences, Inc. announced that it has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC for an upfront payment of $43 million and royalties on worldwide sales.

The company struck the cash-and-share deals to boost its presence in Europe.

Akston Biosciences Corporation, dedicated to accelerating the biologics revolution in Animal Health, today announced the appointment of Linda Rhodes, VMD, PhD to its Board of Directors.